Digitala Vetenskapliga Arkivet

Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Magistral Compounding with 3D Printing: A Promising Way to Achieve Personalized Medicine
Univ Copenhagen, Fac Hlth & Med Sci, Dept Pharm, Social & Clin Pharm Res Grp, Univ Pk 2, DK-2100 Copenhagen O, Denmark..
Univ Copenhagen, Fac Hlth & Med Sci, Dept Pharm, Social & Clin Pharm Res Grp, Univ Pk 2, DK-2100 Copenhagen O, Denmark..
Univ Copenhagen, Fac Hlth & Med Sci, Dept Pharm, Mfg & Mat Res Grp, Copenhagen O, Denmark..
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Farmaceutiska fakulteten, Institutionen för farmaci. Univ Copenhagen, Fac Hlth & Med Sci, Dept Pharm, Social & Clin Pharm Res Grp, Univ Pk 2, DK-2100 Copenhagen O, Denmark.. (Social Pharm Grp)ORCID-id: 0000-0001-5848-8625
Vise andre og tillknytning
2023 (engelsk)Inngår i: Therapeutic Innovation and Regulatory Science, ISSN 2168-4790, E-ISSN 2168-4804, Vol. 57, nr 1, s. 26-36Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background Magistral compounding has always been an integral part of pharmacy practice. The increasing demand worldwide for personalized drug treatments might be accommodated by an increase in magistral compounding. The new, flexible technology of 3D medicine printing could advance this process even further. However, the issue of how 3D medicine printing can be implemented within the existing magistral compounding infrastructure has not been explored. Aims To investigate how 3D printing can be integrated into the existing compounding system by taking regulatory, economic, and profession-oriented aspects into account. Methods Semi-structured interviews were conducted with relevant Dutch stakeholders representing various health institutions, such as health ministries and boards, professional bodies, and different types of pharmacies. Participants were identified through purposeful sampling. Content analysis was applied to identify the main themes. Results A total of 15 Dutch stakeholders were interviewed. It was found that the prevalence of compounding in community pharmacies in the Netherlands has decreased as a result of the practice shifting to specialized compounding pharmacies due to higher costs, lack of space, and the need to fulfill quality requirements. All interviewees considered 3D printing to be a promising compounding technique for community pharmacies, as it offers an automated approach with high digital flexibility and enables adapted formulations, including 'polypills.' Regulatory and quality assurance challenges were considered comparable to those of normal magistral products; however, there remain pending regulatory issues regarding quality control, particularly for Active Pharmaceutical Ingredients containing intermediate feedstock materials (e.g., prefilled cartridges) in 3D printing. 3D printing was believed to become cost effective over time. Conclusion In the Netherlands, specialized compounding pharmacies have largely taken over compounding activities. 3D printing could be introduced within this system; however, challenges regarding how to regulate prefilled cartridges have yet to be addressed. Compounding using 3D printing in regular community pharmacies could enhance patients' individualized treatment; however, this activity would require incentives to stimulate the return of compounding to normal pharmacy practice.

sted, utgiver, år, opplag, sider
Springer Nature, 2023. Vol. 57, nr 1, s. 26-36
Emneord [en]
Compounding, Community pharmacy, Personalized medicine, 3D printing, Regulation, Interviews
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-497360DOI: 10.1007/s43441-022-00436-7ISI: 000837961500001PubMedID: 35943712OAI: oai:DiVA.org:uu-497360DiVA, id: diva2:1740336
Tilgjengelig fra: 2023-03-01 Laget: 2023-03-01 Sist oppdatert: 2023-03-01bibliografisk kontrollert

Open Access i DiVA

fulltekst(730 kB)142 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 730 kBChecksum SHA-512
2239a0079dfc00085d85594efcb244dba50d5a424d85f803b4c7a1ea14a5ada90aea7b3644af057ddf5f9d26c15b4981e2cae4aafe7109059c4a34126ab841ca
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Søk i DiVA

Av forfatter/redaktør
Sporrong, Sofia Kälvemark
Av organisasjonen
I samme tidsskrift
Therapeutic Innovation and Regulatory Science

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 142 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 94 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf